412 related articles for article (PubMed ID: 21901357)
1. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.
Tanaka Y; Yamanaka H; Saito K; Iwata S; Miyagawa I; Seto Y; Momohara S; Nagasawa H; Kameda H; Kaneko Y; Izumi K; Amano K; Takeuchi T
Mod Rheumatol; 2012 Apr; 22(2):186-94. PubMed ID: 21901357
[TBL] [Abstract][Full Text] [Related]
2. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
[TBL] [Abstract][Full Text] [Related]
3. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
[TBL] [Abstract][Full Text] [Related]
4. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
Baumgartner SW; Fleischmann RM; Moreland LW; Schiff MH; Markenson J; Whitmore JB
J Rheumatol; 2004 Aug; 31(8):1532-7. PubMed ID: 15290731
[TBL] [Abstract][Full Text] [Related]
5. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
7. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
Keystone E; Freundlich B; Schiff M; Li J; Hooper M
J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
[TBL] [Abstract][Full Text] [Related]
8. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
Landewé R; van der Heijde D; Klareskog L; van Vollenhoven R; Fatenejad S
Arthritis Rheum; 2006 Oct; 54(10):3119-25. PubMed ID: 17009230
[TBL] [Abstract][Full Text] [Related]
9. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
ter Wee MM; den Uyl D; Boers M; Kerstens P; Nurmohamed M; van Schaardenburg D; Voskuyl AE; Lems WF
Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633
[TBL] [Abstract][Full Text] [Related]
10. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
[TBL] [Abstract][Full Text] [Related]
11. Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis.
Nair SC; Bijlsma JW; van der Werf JH; van der Veen MJ; Linn-Rasker SP; Vreugdenhil S; Lafeber FP; Welsing PM
J Rheumatol; 2013 Sep; 40(9):1505-12. PubMed ID: 23818710
[TBL] [Abstract][Full Text] [Related]
12. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y
Clin Exp Rheumatol; 2016; 34(5):834-841. PubMed ID: 27607196
[TBL] [Abstract][Full Text] [Related]
13. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
14. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
16. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
17. May etanercept and PTH (1-34) association heal erosions in early rheumatoid arthritis? A pilot study.
Migliore A; Massafra U; Bizzi E; Argento G; Diamanti AP; Germano V; Tormenta S; Arduini F; Iannessi F; Granatas M; Laganà B
Eur Rev Med Pharmacol Sci; 2012 Mar; 16(3):363-9. PubMed ID: 22530354
[TBL] [Abstract][Full Text] [Related]
18. Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function.
Nagasawa H; Kameda H; Sekiguchi N; Amano K; Takeuchi T
Clin Exp Rheumatol; 2010; 28(3):365-72. PubMed ID: 20525444
[TBL] [Abstract][Full Text] [Related]
19. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
